AMG 510

Amgen, Inc. (NASDAQ: AMGN) shares were pulling back Monday following the presentation of new data on its investigational compound for solid tumors. Good, But Not Good Enough Amgen said in a Sunday statement that new data from the Phase 1 study of AMG 510 presented as an oral presentation...